Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

Prostate

Volumn 73, Issue 3, 2013, Pages 227-235

  Perdonà, Sisto ^a   Bruzzese, Dario ^b   Ferro, Matteo ^b   Autorino, Riccardo ^c   Marino, Ada ^b   Mazzarella, Claudia ^b   Perruolo, Giuseppe ^b   Longo, Michele ^b   Spinelli, Rosa ^b   Di Lorenzo, Giuseppe ^b   Oliva, Andrea ^d   De Sio, Marco ^c   Damiano, Rocco ^e   Altieri, Vincenzo ^f   Terracciano, Daniela ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

Author keywords

p2PSA; PCA3; phi; prostate biopsy; prostate cancer

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84872779073     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22561     Document Type: Article

References (32)

1. Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H,. PCA3: From basic molecular science to the clinical lab. Cancer Lett 2011; 301 (1): 1-6.
2. Roobol MJ, Haese A, Bjartell A,. Tumour markers in prostate cancer III: Biomarkers in urine. Acta Oncol 2011; 50 (Suppl 1): 85-89.
3. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G,. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57 (6): 921-927.
4. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54 (5): 1081-1088.
5. Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Bastien L, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, Van Gils MP, Schalken JA, de La Taille A,. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: Does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 2010; 106 (8): 1143-1147.
6. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, Horninger W, Klocker H, Mikolajczyk SD,. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. Urol 2003; 170 (6 Pt 1): 2181-2185.
7. Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW,. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009; 15 (23): 7316-7321.
8. Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW,. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011; 77 (3): 763, e761-e766.
9. Ferro M, Bruzzese D, Perdona S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D,. Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 2012; 413 (15-16): 1274-1278.
10. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE,. Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 2009; 8 (1): 113-117.
11. Semjonow A, Kopke T, Eltze E, Pepping-Schefers B, Burgel H, Darte C,. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010; 43 (10-11): 926-928.
12. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H,. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52 (6): 1089-1095.
13. Rodriguez-Covarrubias F, Gonzalez-Ramirez A, Aguilar-Davidov B, Castillejos-Molina R, Sotomayor M, Feria-Bernal G,. Extended sampling at first biopsy improves cancer detection rate: Results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy. J Urol 2011; 185 (6): 2132-2136.
14. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ,. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183 (2): 534-538.
15. Royston P, Altman DG,. Regression using fractional polynomials of continous covariate: Parsimonious parametric modelling. Appl Stat 1994; 43: 429-467.
16. Sauerbrei W, Royston P,. Building multivariable prognostic and diagnostic models: Transformation of the predictors by using fractional polynomials. J Royal Stat Soc 1999; 162: 71-94.
17. Obuchowski NA, McClish DK,. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med 1997; 16 (13): 1529-1542.
18. Guo W,. A note on adaptive Bonferroni and Holm procedures under dependence. Biometrika 2009; 96: 1012-1018.
19. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD,. Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54 (8): 774-781.
20. Vickers AJ, Elkin EB,. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 2006; 26 (6): 565-574.
21. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A,. Tumor markers in prostate cancer I: Blood-based markers. Acta Oncol 2011; 50 (Suppl 1): 61-75.
22. Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda G, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F,. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2011; 61 (3): 455-466.
23. Ploussard G, de la Taille A,. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7 (2): 101-109.
24. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H,. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011; 60 (5): 1045-1054.
25. de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A,. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011; 185 (6): 2119-2125.
26. Lee GL, Dobi A, Srivastava S,. Prostate cancer: Diagnostic performance of the PCA3 urine test. Nat Rev Urol 2011; 8 (3): 123-124.
27. Roobol MJ,. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 2011; 21 (3): 225-229.
28. Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H, Vickers A,. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: An independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010; 10: 635.
29. Nguyen PN, Violette P, Chan S, Tanguay S, Kassouf W, Aprikian A, Chen JZ,. A panel of TMPRSS2: ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol 2011; 59 (3): 407-414.
30. Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llaurado M, Colas E, Pedrola N, Montes M, Sequeiros T, Ertekin T, Majem B, Planas J, Ruiz A, Abal M, Sanchez A, Morote J, Reventos J, Doll A,. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 2011; 71 (16): 1736-1745.
31. Perdona S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P, Franco R, Azzarito G, Scala S, Arra C, De Sio M, Autorino R,. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: Head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 2011; 59 (1): 81-87.
32. Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K,. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009; 69 (2): 198-207.